Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Préréhabilitation multicomponentielle chez les personnes âgées atteintes d'un cancer du sein (PREHAB-BC65)

24 septembre 2026 mis à jour par: Nicolás Martínez Velilla, Fundacion Miguel Servet

Multidimensional Oncogeriatric Prehabilitation in Older Adults With Breast Cancer: A Randomized Controlled Trial Integrating Frailty and Biomarker Assessment

Older adults with breast cancer frequently present with frailty, decreased functional reserve, and increased risk of postoperative complications. Prehabilitation programs have emerged as a promising strategy to improve physical function and clinical outcomes; however, evidence in geriatric oncology remains limited, particularly regarding the role of biological markers in predicting response to such interventions.

This study aims to evaluate the effectiveness of a multicomponent prehabilitation program in older adults with breast cancer, focusing on functional status, clinical outcomes, and quality of life. In addition, the study seeks to characterize biological markers associated with frailty and treatment response, with the goal of identifying potential predictors of benefit from prehabilitation.

Participants will undergo a structured prehabilitation intervention including physical exercise, nutritional optimization, and comprehensive geriatric assessment. Clinical, functional, and biomarker data will be collected longitudinally.

The results of this study may contribute to improving personalized care strategies in geriatric oncology and to identifying patients who are most likely to benefit from prehabilitation programs.

Aperçu de l'étude

Description détaillée

This study is a prospective, randomized, controlled, single-blind clinical trial designed to evaluate the effectiveness of a multicomponent prehabilitation program in older adults with breast cancer, incorporating biological characterization to explore predictors of treatment response.

The trial will be conducted at the Navarre University Hospital (Pamplona, Spain). A total of 90 ambulatory patients aged 65 years or older with a confirmed diagnosis of breast cancer will be recruited and randomly assigned in a 1:1:1 ratio to usual care, a home-based multicomponent exercise program based on the Vivifrail methodology, or a supervised hospital-based intervention. All participants will undergo baseline frailty screening followed by a comprehensive geriatric assessment to characterize functional, cognitive, nutritional, and clinical status. Assessments will be repeated at predefined time points throughout the perioperative period and during follow-up.

The intervention is structured into preoperative and postoperative phases and includes individualized multicomponent exercise, nutritional optimization, and targeted management of geriatric syndromes. The hospital-based intervention consists of supervised sessions over six weeks (including a 2-week preoperative phase and a 4-week postoperative phase), while the home-based intervention is adapted to baseline functional status.

Clinical, functional, and biological data will be collected longitudinally to evaluate the impact of the intervention and to identify predictors of clinical outcomes and treatment response.

Type d'étude

Interventionnel

Inscription (Estimé)

90

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Lieux d'étude

    • Navarre
      • Pamplona, Navarre, Espagne, 31008
        • Recrutement
        • Hospital Universitario de Navarra
        • Contact:
        • Contact:
        • Chercheur principal:
          • Nicolás Martínez Velilla, MD, PhD
        • Sous-enquêteur:
          • Bernardo Abel Cedeño Veloz, MD, PhD
        • Sous-enquêteur:
          • Susana de la Cruz Sánchez, MD
        • Sous-enquêteur:
          • Sara Esteban Gordillo, MD
        • Sous-enquêteur:
          • Natalia Moras Pérez, MD
        • Sous-enquêteur:
          • Fabricio Zambom Ferraresi, PhD
        • Sous-enquêteur:
          • Marta Lorente Escudero, MD
        • Sous-enquêteur:
          • Lucía Lozano Vicario, MD, PhD

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

65 ans et plus (Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Age ≥65 years
  • Diagnosis of breast cancer requiring elective surgery with curative intent
  • Candidate for prehabilitation program before surgery
  • Ability to walk (with or without assistive devices)
  • Ability to provide informed consent

Exclusion Criteria:

  • Urgent or emergency surgery
  • Severe cognitive impairment precluding participation in the intervention
  • Severe functional dependency (e.g., bedridden patients)
  • Medical contraindication to physical exercise
  • Life expectancy <3 months

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Seul

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Aucune intervention: Usual Care

Participants receive standard clinical care according to routine practice, including management by oncology and surgical teams. Identified geriatric conditions are communicated to the treating physician for appropriate management.

Expérimental: Home-based Multicomponent Prehabilitation (Vivifrail)

Participants perform a home-based multicomponent exercise program based on the Vivifrail methodology, including strength, endurance, balance, and flexibility training over six weeks, comprising a 2-week preoperative phase and a 4-week postoperative phase. The program is tailored according to baseline functional status and supported by caregiver supervision. Participants also receive comprehensive geriatric assessment and nutritional optimization.

Participants perform a structured home-based multicomponent exercise program based on the Vivifrail methodology, including strength, endurance, balance, and flexibility training over six weeks. The program is individualized according to baseline functional status.

Participants undergo comprehensive geriatric assessment with targeted interventions including nutritional optimization, medication review, and management of geriatric syndromes.

Expérimental: Supervised Multicomponent Prehabilitation

Participants receive a supervised multicomponent exercise program delivered in the hospital setting, including aerobic, resistance, balance, and flexibility training over six weeks, including a 2-week preoperative phase and a 4-week postoperative phase. The intervention is combined with comprehensive geriatric assessment, nutritional optimization, and individualized management of geriatric syndromes.

Participants undergo comprehensive geriatric assessment with targeted interventions including nutritional optimization, medication review, and management of geriatric syndromes.

Participants receive a structured, supervised multicomponent exercise program delivered in a hospital setting, including aerobic, strength, balance, and flexibility training over six weeks.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Change in physical function assessed by Short Physical Performance Battery (SPPB)
Délai: Baseline to the end of the 6-week intervention period

Physical function will be assessed using the Short Physical Performance Battery (SPPB), a validated tool in older adults (score range 0-12, higher scores indicate better performance). The primary outcome will be the change in SPPB score from baseline to the end of the 6-week intervention period.

Baseline to the end of the 6-week intervention period

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Incidence of postoperative complications
Délai: Within 30 days after surgery

Occurrence of postoperative complications within 30 days after surgery, classified according to the Clavien-Dindo classification.

Within 30 days after surgery
Length of hospital stay
Délai: From date of surgery until hospital discharge, with a maximum follow-up of 30 days postoperatively

Number of days from surgery to hospital discharge.

From date of surgery until hospital discharge, with a maximum follow-up of 30 days postoperatively
Functional decline after surgery
Délai: Baseline to 30 days after surgery

Functional decline defined as a decrease in the Short Physical Performance Battery (SPPB) score (range 0 to 12, with higher scores indicating better physical performance) or loss of independence in activities of daily living compared to baseline.

Baseline to 30 days after surgery
Health-related quality of life
Délai: Baseline to 30 days after surgery

Health-related quality of life assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30; scores transformed to a 0-100 scale, where higher scores indicate better functioning or worse symptoms depending on the domain).

Baseline to 30 days after surgery
Adherence to the intervention
Délai: During the 6-week intervention period

Percentage of prescribed exercise sessions completed by participants.

During the 6-week intervention period

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Les enquêteurs

  • Directeur d'études: Marta Lorente Escudero, MD, Navarre Health Service (SNS-O), Navarre University Hospital (HUN), Pamplona, Spain

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

4 décembre 2024

Achèvement primaire (Estimé)

1 mars 2027

Achèvement de l'étude (Estimé)

1 juin 2028

Dates d'inscription aux études

Première soumission

31 mars 2026

Première soumission répondant aux critères de contrôle qualité

13 avril 2026

Première publication (Réel)

15 avril 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

29 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

24 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Individual participant data will not be shared due to data protection regulations and institutional policies. De-identified data may be available from the corresponding author upon reasonable request, subject to ethical approval and data sharing agreements.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner